Stifel Financial Corp Invests $218,000 in Tempus AI, Inc. (NASDAQ:TEM)

Stifel Financial Corp bought a new position in Tempus AI, Inc. (NASDAQ:TEM) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 3,846 shares of the company’s stock, valued at approximately $218,000.

Several other large investors have also recently modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. lifted its stake in Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the period. Captrust Financial Advisors bought a new position in shares of Tempus AI during the third quarter valued at $2,726,000. Sigma Planning Corp bought a new stake in Tempus AI during the 3rd quarter valued at about $1,323,000. Dakota Wealth Management bought a new stake in shares of Tempus AI in the 3rd quarter worth $1,185,000. Finally, Davidson Kempner Capital Management LP purchased a new position in Tempus AI in the 2nd quarter worth about $2,271,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TEM. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital increased their price target on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Guggenheim began coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Stock Down 0.5 %

Shares of NASDAQ:TEM opened at $35.12 on Monday. The stock’s 50 day moving average is $50.06. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insiders Place Their Bets

In other news, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now owns 27,894 shares of the company’s stock, valued at $1,166,248.14. This trade represents a 2.17 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 845,041 shares of company stock worth $35,125,473.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.